comms@paragonbiosci.com

56 items

February 28, 2025

Groundbreaking Achievements and Pivotal Milestones for Paragon and its Portfolio Companies
In 2024, Paragon and its [...]
February 27, 2025

Emalex Biosciences’ Lead Candidate Meets Primary and Secondary Endpoints in Phase 3 Tourette Syndrome Study
Topline data from Phase 3 study in [...]
November 19, 2024

Emalex Biosciences Named “Neuroscience Therapeutics Company Of The Year” by BioTech Breakthrough
Annual Awards Program Recognizes Innovation in the [...]
April 9, 2024

Article Highlights Positive Study Results Presented at AAN Annual Meeting
By Mary Beth Nierengarten, April 1, 2024 [...]
November 15, 2023

Harmony Biosciences Ranked Among Top 25 Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500™
Ranking attributed to 7,204% growth from fiscal [...]
September 27, 2023

Evozyne Announces $81 Million Financing Round to Advance Generative AI for Therapeutic Discovery and Drug Development
New investor OrbiMed expects platform to reduce [...]
August 14, 2023

Harmony Biosciences to Acquire Zynerba Pharmaceuticals, Inc.
Acquisition expands pipeline and diversifies portfolio to [...]
April 24, 2023

Harmony Biosciences Announces Jeffrey M. Dayno, M.D. Appointed President & Chief Executive Officer
– Dr. Dayno joins Harmony Biosciences Board [...]